National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for colorectal cancer. HTA ID: 21002

Pembrolizumab is indicated as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 08/02/2021
Rapid review completed 03/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/03/2021
Pre-submission consultation with Applicant 21/04/2021
Full submission received from Applicant 21/01/2022
Preliminary Review sent to Applicant 10/06/2022
NCPE assessment re-commenced 08/07/2022
Factual accuracy check sent to Applicant 07/09/2022
NCPE assessment re-commenced 19/09/2022
NCPE assessment completed 13/10/2022
NCPE assessment outcome The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.